Imperial College London
Mr Joseph Eliahoo

MrJosephEliahoo

Faculty of Medicine, School of Public Health

Statistical Consultant
 
 
 
//

Contact

 

j.eliahoo Website

 
 
//

Assistant

 

Mrs Krupa Shukla +44 (0)20 7594 1754

 
//

Location

 

//

Summary

 

Publications

Citation

BibTex format

@article{Youssaf:2019:10.1016/j.jceh.2019.08.001,
author = {Youssaf, A and Kim, J and Eliahoo, J and Taylor-Robinson, S and Khan, S},
doi = {10.1016/j.jceh.2019.08.001},
journal = {Journal of Clinical and Experimental Hepatology},
pages = {740--748},
title = {Ablative therapy for unresectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis},
url = {http://dx.doi.org/10.1016/j.jceh.2019.08.001},
volume = {9},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Intrahepatic cholangiocarcinoma (iCCA) is usually a fatal malignancy with rising incidence globally. Surgical resection currently remains the only curative treatment. However, as only a minority of iCCA are amenable to resection, new therapeutic modalities are needed. Aims: Our aims were to systematically review and perform a meta-analysis on the existing literature regarding the use of ablative therapies in iCCA; and to assess their efficacy as a treatment modality by calculating pooled survival results and investigate associations between prognostic factors and survival. Methods: A comprehensive search of the PubMed database for relevant articles was performed. Studies assessing survival in patients with iCCA undergoing ablation were included. Data were extracted on patient, tumour and treatment characteristics and survival. Random effects meta-analysis was used to pool the data. Galbraith plots were used to investigate heterogeneity; bubble plots were formulated using regression-based meta-analysis. Results: 10 studies were included in the final analysis, yielding an aggregate of 206 patients (69.5% male, median age 51.2-72.5) and 320 tumours. 70.4% of patients were recurrent cases of iCCA and 29.6% primary iCCA. Median overall survival ranged from 8.7 to 52.4 months. Pooled survival rates for 1, 3 and 5-year survival were 76% (95% CI: 68-83%), 33% (21-44%) and 16% (7-26%), respectively. No significant association was found between the median age, number of tumours or median tumour size and 1-year survival. Conclusion: Ablative therapies display promising potential as treatment modalities for iCCA. However, further research is necessary to validate these findings.
AU  - Youssaf,A
AU  - Kim,J
AU  - Eliahoo,J
AU  - Taylor-Robinson,S
AU  - Khan,S
DO  - 10.1016/j.jceh.2019.08.001
EP  - 748
PY  - 2019///
SN  - 0973-6883
SP  - 740
TI  - Ablative therapy for unresectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis
T2  - Journal of Clinical and Experimental Hepatology
UR  - http://dx.doi.org/10.1016/j.jceh.2019.08.001
UR  - https://www.sciencedirect.com/science/article/pii/S0973688319302075?via%3Dihub
UR  - http://hdl.handle.net/10044/1/72810
VL  - 9
ER  -
Download